Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Pituitary Neoplasms 7Acromegaly 4Prostatic Neoplasms 3Carcinoid Tumor 3Pituitary ACTH Hypersecretion 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2Neoplasms 2Growth Disorders 2Gigantism 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Thyroid Neoplasms 1Serotonin Syndrome 1Prolactinoma 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Nelson Syndrome 1Myelodysplastic Syndromes 1Meningioma 1Melanoma 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Dumping Syndrome 1

Interventions

vandetanib 7Sorafenib 6Magnetic Resonance Spectroscopy 6lenvatinib 5cabozantinib 5Sunitinib 4Iodine-131 4selpercatinib 3AZD 6244 3trametinib 2tipifarnib 2durvalumab 2dabrafenib 2alectinib 2Triiodothyronine 2Thyroxine 2Thyrotropin Alfa 2Paclitaxel 2Nivolumab 2Ipilimumab 2Fluorodeoxyglucose F18 2Everolimus 2Bortezomib 2Axitinib 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2tremelimumab 1temsirolimus 1tanespimycin 1sapanisertib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid Neoplasms × pasireotide × Clear all
NCT01270321 2021-02-17

Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer

Emory University

Phase 2 Completed
42 enrolled 11 charts
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡